ORIGINAL ARTICLE
Ahead of Print

Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer


1 Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 20032, China
2 Department of Oncology, Fudan University Shanghai Medical College, Shanghai 200032, China
3 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Correspondence Address:
Bo Dai,
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 20032, China; Department of Oncology, Fudan University Shanghai Medical College, Shanghai 200032, China

Ding-Wei Ye,
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 20032, China; Department of Oncology, Fudan University Shanghai Medical College, Shanghai 200032, China

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aja.aja_85_18

PMID: 30560837

This study investigated the clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 146 patients with docetaxel-naïve group (103 cases) and docetaxel-resistant group (43 cases) were enrolled from the Shanghai Cancer Center (Shanghai, China) in this retrospective cohort study. The efficacy endpoints were prostate-specific antigen response rate, prostate-specific antigen progression-free survival, clinical/radiographic progression-free survival, and overall survival in response to abiraterone plus prednisone. Significantly higher prostate-specific antigen response rate was found in docetaxel-naïve group (54.4%, 56/103) compared to docetaxel-resistant group (34.9%, 15/43) (P = 0.047). In addition, significantly higher median prostate-specific antigen progression-free survival (14.0 vs 7.7 months, P = 0.005), clinical or radiographic progression-free survival (17.0 vs 12.5 months, P = 0.003), and overall survival (27.0 vs 18.0 months, P = 0.016) were found in docetaxel-naïve group compared to docetaxel-resistant group, respectively. The univariate and multivariate analyses indicated that lower albumin and visceral metastases were independent significant predictors for shorter overall survival. To sum up, our data suggested that abiraterone plus prednisone was efficient in both docetaxel-naïve and docetaxel-resistant Chinese patients. Moreover, higher PSA response rate and longer overall survival were observed in the docetaxel-naïve group, which suggested that abiraterone was more effective for docetaxel- naïve patients than for docetaxel failures.


[FULL TEXT] [PDF]
Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Lin GW
    -  Li GX
    -  Dai B
    -  Ye DW
    -  Kong YY
    -  Wang Y
    -  Shen YJ
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed321    
    PDF Downloaded45    
    Cited by others 1    

Recommend this journal